Aim. The aim of this study is to evaluate the effects of the synbiotic Bifidobacterium lactis B94 plus inulin addition to the standard triple therapy on Helicobacter pylori (H. pylori) infection eradication rates. Methods. Children aged 6-16 years who had biopsy proven H. pylori infection were randomly classified into two groups. The first group received the standard triple therapy consisting of amoxicillin + clarithromycin + omeprazole. The second group was treated with the standard triple therapy and Bifidobacterium lactis B94 (5 x 10(9) CFU/dose) plus inulin (900mg) for 14 days, concurrently. Eradication was determined by 14 C-urea breath test 4-6 weeks after therapy discontinuation. Results. From a total of 69 H. pylori infected children (F/M = 36/33; mean +/- SD = 11.2 + 3.0 years), eradication was achieved in 20/34 participants in the standard therapy group and 27/35 participants in the synbiotic group. The eradication rates were not significantly different between the standard therapy and the synbiotic groups [intent-totreat, 58.8% and 77.1%, resp., p = 0.16; per-protocol, 64.5% and 81.8%, resp., p = 0.19]. There was no difference between the groups in terms of symptom relief (p = 0.193). The reported side effects were ignorable. Conclusion. Considering the eradication rates, synbiotic addition to therapy showed no superiority over the standard triple therapy conducted alone. This trial is registered with NCT03165253.

Yazar Ustundag, Gonca Handan
Altuntas, Halime
Soysal, Yasemin Dilek
Kokturk, Furuzan
Yayın Türü Article
Tek Biçim Adres https://hdl.handle.net/20.500.12628/3573
Tek Biçim Adres 10.1155/2017/8130596
Koleksiyonlar Araştırma Çıktıları | WoS | Scopus | TR-Dizin | PubMed | SOBİAD
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu
Dergi Adı CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
Sayfalar -
Yayın Yılı 2017
Yazar
[dc.contributor.author]
Ustundag, Gonca Handan
Yazar
[dc.contributor.author]
Altuntas, Halime
Yazar
[dc.contributor.author]
Soysal, Yasemin Dilek
Yazar
[dc.contributor.author]
Kokturk, Furuzan
Yayın Yılı
[dc.date.issued]
2017
Yayıncı
[dc.publisher]
HINDAWI LTD
Yayın Türü
[dc.type]
article
Özet
[dc.description.abstract]
Aim. The aim of this study is to evaluate the effects of the synbiotic Bifidobacterium lactis B94 plus inulin addition to the standard triple therapy on Helicobacter pylori (H. pylori) infection eradication rates. Methods. Children aged 6-16 years who had biopsy proven H. pylori infection were randomly classified into two groups. The first group received the standard triple therapy consisting of amoxicillin + clarithromycin + omeprazole. The second group was treated with the standard triple therapy and Bifidobacterium lactis B94 (5 x 10(9) CFU/dose) plus inulin (900mg) for 14 days, concurrently. Eradication was determined by 14 C-urea breath test 4-6 weeks after therapy discontinuation. Results. From a total of 69 H. pylori infected children (F/M = 36/33; mean +/- SD = 11.2 + 3.0 years), eradication was achieved in 20/34 participants in the standard therapy group and 27/35 participants in the synbiotic group. The eradication rates were not significantly different between the standard therapy and the synbiotic groups [intent-totreat, 58.8% and 77.1%, resp., p = 0.16; per-protocol, 64.5% and 81.8%, resp., p = 0.19]. There was no difference between the groups in terms of symptom relief (p = 0.193). The reported side effects were ignorable. Conclusion. Considering the eradication rates, synbiotic addition to therapy showed no superiority over the standard triple therapy conducted alone. This trial is registered with NCT03165253.
Açıklama
[dc.description]
WOS: 000402922400001
Açıklama
[dc.description]
PubMed: 28656129
Kayıt Giriş Tarihi
[dc.date.accessioned]
2019-12-23
Açık Erişim Tarihi
[dc.date.available]
2019-12-23
Yayın Dili
[dc.language.iso]
eng
Haklar
[dc.rights]
info:eu-repo/semantics/openAccess
ISSN
[dc.identifier.issn]
2291-2797
Dergi Adı
[dc.relation.journal]
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
Tek Biçim Adres
[dc.identifier.uri]
https://dx.doi.org/10.1155/2017/8130596
Tek Biçim Adres
[dc.identifier.uri]
https://hdl.handle.net/20.500.12628/3573
Görüntülenme Sayısı ( Şehir )
Görüntülenme Sayısı ( Ülke )
Görüntülenme Sayısı ( Zaman Dağılımı )
Görüntülenme
5
09.12.2022 tarihinden bu yana
İndirme
1
09.12.2022 tarihinden bu yana
Son Erişim Tarihi
18 Ocak 2024 15:29
Google Kontrol
Tıklayınız
therapy standard eradication triple synbiotic groups pylori between participants addition effects Bifidobacterium lactis inulin infection different [intent-totreat years) achieved significantly ignorable NCT03165253 registered conducted superiority showed Considering Conclusion per-protocol reported relief symptom difference consisting received
6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms